• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

作者信息

Hellmann Matthew D, Callahan Margaret K, Awad Mark M, Calvo Emiliano, Ascierto Paolo A, Atmaca Akin, Rizvi Naiyer A, Hirsch Fred R, Selvaggi Giovanni, Szustakowski Joseph D, Sasson Ariella, Golhar Ryan, Vitazka Patrik, Chang Han, Geese William J, Antonia Scott J

出版信息

Cancer Cell. 2019 Feb 11;35(2):329. doi: 10.1016/j.ccell.2019.01.011.

DOI:10.1016/j.ccell.2019.01.011
PMID:30753829
Abstract
摘要

相似文献

1
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.肿瘤突变负荷以及纳武利尤单抗单药治疗及联合伊匹木单抗治疗小细胞肺癌的疗效
Cancer Cell. 2019 Feb 11;35(2):329. doi: 10.1016/j.ccell.2019.01.011.
2
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.纳武利尤单抗联合或不联合伊匹单抗治疗转移性肉瘤（Alliance A091401）：两项开放标签、非比较、随机、2 期临床试验。
Lancet Oncol. 2018 Mar;19(3):416-426. doi: 10.1016/S1470-2045(18)30006-8. Epub 2018 Jan 19.
3
Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal: ORIGINAL ARTICLE: Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017; 377:1345-56.纳武利尤单抗对比伊匹单抗用于晚期黑色素瘤的治疗：一项关键性评价：原创文章：Wolchok JD, Chiarion-Sileni V, Gonzalez R 等。纳武利尤单抗联合伊匹单抗治疗晚期黑色素瘤的总生存期。《新英格兰医学杂志》2017; 377:1345-56.
Br J Dermatol. 2018 Aug;179(2):296-300. doi: 10.1111/bjd.16785. Epub 2018 Jun 5.
4
Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.免疫检查点抑制剂在小细胞肺癌中的作用。
Am J Ther. 2018 May/Jun;25(3):e349-e356. doi: 10.1097/MJT.0000000000000686.
5
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.纳武利尤单抗联合伊匹单抗或纳武利尤单抗单药治疗黑色素瘤脑转移瘤：一项多中心随机 2 期研究。
Lancet Oncol. 2018 May;19(5):672-681. doi: 10.1016/S1470-2045(18)30139-6. Epub 2018 Mar 27.
6
Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials.纳武单抗单药治疗或联合伊匹单抗治疗转移性黑色素瘤：随机对照试验的系统评价和荟萃分析
Melanoma Res. 2018 Oct;28(5):371-379. doi: 10.1097/CMR.0000000000000467.
7
Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma.伊匹木单抗和纳武单抗联合免疫检查点阻断疗法用于晚期黑色素瘤的治疗
Expert Opin Biol Ther. 2016;16(3):389-96. doi: 10.1517/14712598.2016.1141195. Epub 2016 Feb 1.
8
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.新辅助与辅助伊匹单抗联合纳武利尤单抗治疗 III 期黑色素瘤的比较。
Nat Med. 2018 Nov;24(11):1655-1661. doi: 10.1038/s41591-018-0198-0. Epub 2018 Oct 8.
9
Nivolumab: A Review in Advanced Melanoma.纳武利尤单抗：晚期黑色素瘤的治疗药物评价。
Drugs. 2015 Aug;75(12):1413-24. doi: 10.1007/s40265-015-0442-6.
10
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.外周血临床实验室变量与黑色素瘤患者接受纳武利尤单抗和伊匹单抗联合免疫治疗后的结局相关。
Cancer Med. 2018 Mar;7(3):690-697. doi: 10.1002/cam4.1356. Epub 2018 Feb 22.

引用本文的文献

1
Identification of novel gene-based risk score for prognosis in prostate cancer.前列腺癌预后新型基因风险评分的鉴定
Sci Rep. 2025 Jul 1;15(1):22128. doi: 10.1038/s41598-025-03800-3.
2
Immune Checkpoint Inhibition for Hepatocellular Carcinoma, Cholangiocarcinoma, and Combined Hepatocellular-Cholangiocarcinoma.免疫检查点抑制剂治疗肝细胞癌、胆管癌及肝内胆管癌合并肝细胞癌
World J Oncol. 2025 Jun;16(3):243-253. doi: 10.14740/wjon2571. Epub 2025 May 13.
3
The current and emerging immunotherapy paradigm in small-cell lung cancer.小细胞肺癌当前及新出现的免疫治疗模式
Nat Cancer. 2025 Jun 5. doi: 10.1038/s43018-025-00992-5.
4
Genomic Profiling of Extensive Stage Small-Cell Lung Cancer Patients Identifies Molecular Factors Associated with Survival.广泛期小细胞肺癌患者的基因组分析确定与生存相关的分子因素。
Lung Cancer (Auckl). 2025 Feb 20;16:11-23. doi: 10.2147/LCTT.S492825. eCollection 2025.
5
TMBocelot: an omnibus statistical control model optimizing the TMB thresholds with systematic measurement errors.TMBocelot：一种通过系统测量误差优化肿瘤突变负荷（TMB）阈值的综合统计控制模型。
Front Immunol. 2025 Jan 20;15:1514295. doi: 10.3389/fimmu.2024.1514295. eCollection 2024.
6
Value of the lung immune prognostic index in patients with advanced small cell lung cancer treated with programmed death-ligand 1 and programmed death-1 inhibitors in the Chinese alpine region.肺免疫预后指数在中国高寒地区接受程序性死亡配体1和程序性死亡1抑制剂治疗的晚期小细胞肺癌患者中的价值
Front Oncol. 2024 Sep 26;14:1411548. doi: 10.3389/fonc.2024.1411548. eCollection 2024.
7
A random survival forest-based pathomics signature classifies immunotherapy prognosis and profiles TIME and genomics in ES-SCLC patients.基于随机生存森林的病理组学特征可对广泛期小细胞肺癌患者的免疫治疗预后进行分类，并描绘免疫微环境和基因组特征。
Cancer Immunol Immunother. 2024 Oct 3;73(12):241. doi: 10.1007/s00262-024-03829-9.
8
Clinical characteristics and influencing factors of anti-PD-1/PD-L1-related severe cardiac adverse event: based on FAERS and TCGA databases.抗 PD-1/PD-L1 相关严重心脏不良事件的临床特征及影响因素：基于 FAERS 和 TCGA 数据库。
Sci Rep. 2024 Sep 27;14(1):22199. doi: 10.1038/s41598-024-72864-4.
9
Characteristics of molecular subtypes and cinical outcomes in the immunotherapy Queue of extensive-stage small cell lung cancer patients.广泛期小细胞肺癌免疫治疗队列中分子亚型特征和临床结局。
BMC Pulm Med. 2024 Aug 29;24(1):423. doi: 10.1186/s12890-024-03221-4.
10
Serum albumin and derived neutrophil-to-lymphocyte ratio are potential predictive biomarkers for immune checkpoint inhibitors in small cell lung cancer.血清白蛋白和衍生的中性粒细胞与淋巴细胞比值是小细胞肺癌免疫检查点抑制剂的潜在预测生物标志物。
Front Immunol. 2024 Jun 7;15:1327449. doi: 10.3389/fimmu.2024.1327449. eCollection 2024.